Bladder Cancer VL

High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi

Details
Bacillus Calmette-Guerin (BCG) has been the standard of care for patients with non muscle-invasive bladder cancer for decades. However, within five years of the first instillation of BCG therapy, about 50% of tumors recur, and 20% of tumors will progress. To overcome BCG resistance, we need to understand the mechanisms of a BCG therapeutic effect and identify molecular correlates that can predict...

Vicineum for High-Risk Non-Muscle-Invasive BCG Unresponsive Bladder Cancer - Rian J. Dickstein

Details
Rian Dickstein, MD, FACS, joins Ashish Kamat, MD, MBBS proving a background of the use of Vicineum® for patients with bacillus calmette-guerin (BCG) unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). Vicineum is a recombinant fusion protein antibody linked to a variant of pseudomonas exotoxin A (ETA) which is administered intravesically for 2 hours twice weekly with induction x 6 w...

The Role of the PD-L1 Checkpoint in BCG Resistance - Max Kates

Details
An augmented presentation from the Bladder Cancer Advocacy Network’s (BCAN) Think Tank 2020 — talk by and discussion with Dr Max Kates PD-L1 was found to be a mediator of bladder-cancer stage progression in a 2007 Mayo Clinic study by Inman et al. A primary observation was that as local tumor stage advanced, levels of PD-L1 expressed by tumor cells increased. Another key discovery was that the maj...

Variant Histology Urothelial Carcinoma: A Patient Case - Makarand Khochikar

Details
Ashish Kamat, MD, welcomes Makarand Khochikar, President of the Urological Society of India – West zone and Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital in Miraj joins to discuss a bladder cancer case from Dr. Khockikar’s case files. In this particular case, Dr. Khockikar reviews the cystoscopy of a 65-year-old male presented with intermittent hematuria and...

T2 N0 M0 High-grade Urothelial Carcinoma Patient Case Study with Cushingoid Features Undergoing Radical Cystectomy in Neobladder - Makarand Khochikar

Details
In a conversation with Ashish Kamat, MD, MBBS, Makarand Khochikar, MS DNB, Dip Urol, FRCS, FEBU, presents a bladder cancer case study focusing on a patient with invasive T2 N0 M0 high-grade urothelial carcinoma. Dr. Khochikar describes both the process of perioperative counseling with the patient and the radical cystectomy that was surgically performed. Dr. Khochikar walks through the procedure an...

Clinically Node Positive Bladder Cancer and The Timing of Surgery - Neema Navai

Details
Ashish Kamat, MD, MBBS welcomes Neema Navai, MD, to this Bladder Cancer Center of Excellence discussion. Dr. Navai researches minimally metastatic and metastatic bladder cancer where surgical therapy can be implemented. Starting with a case study of a patient diagnosed with bladder cancer with an involved pelvic lymph node, Dr. Navai describes how outcomes regarding the use of surgery and chemothe...

The Management of Bladder Cancer During Pregnancy - Makarand Khochikar

Details
Makarand Khochikar, MS DNB, Dip Urol, FRCS, FEBU, presents a case study evaluating the care of a pregnant woman with bladder cancer, in a discussion with Ashish Kamat, MD, MBBS. Dr. Kamat discusses balancing the health of the mother and the health of the fetus, and Dr. Khochikar reviews the treatment the patient was given, including muscle-sparing resection of the tumor. Dr. Khochikar and Dr. Kama...

Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay

Details
Justin Matulay, MD, joins Ashish Kamat, MD, MBBS, to review his work assessing the variability in guideline management and adherence for non-muscle Invasive Bladder Cancer (NMIBC) among members of the Society for Urologic Oncology (SUO). As bladder cancer poses a significant risk to the population and most diagnoses are non-muscle invasive, Dr. Matulay and colleagues at MD Anderson Cancer Center w...

Urinary Diversion in Women Following Radical Cystectomy - Renu Eapen

Details
Ashish Kamat, MD, MBBS welcomes Renu Eapen, MD, to the UroToday Bladder Cancer Center of Excellence to dissect the gender-related differences in oncological and functional outcomes post-radical cystectomy. Women have been shown to face worse oncological outcomes with bladder cancer; explanations for this include social determinants such as initial diagnosis of urinary tract infection (UTI) prior t...

Radical Cystectomy and The Importance of Oncological Concepts in Surgical Approach - Rafael Sanchez Salas

Details
Rafael Sanchez Salas, MD, from the Montsouris Institute in France joins Ashish Kamat, MD, MBBS, to provide his perspective on essential components of a radical cystectomy. Radical cystectomy is the standard of care for patients with muscle-invasive bladder cancer and those with high-grade non-muscle invasive bladder cancer, and it comes with the risk of complications and adverse outcomes. Dr. Sala...
email news signup